Currently available dosage forms and the route of administration of drugs for COVID-19 treatments

Abstract

COVID-19 has been labeled a worldwide pandemic in 2020. The mortality rates have raised rapidly due to restricted treatment options. The COVID-19 outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously expanding. In the pathophysiology of this illness, the patient's immune response is crucial. In extreme cases, the mediators of this inflammatory factor were shown to reach the cytokine at maximum amounts. Due to alterations in drug pharmacokinetics, a hyperinflammatory state can produce severe anomalies in transporters and drug metabolic machinery, resulting in unforeseen therapeutic responses. The present situation considers the necessity for medications to treat to alleviate and eliminate the epidemic. COVID-19 continues to spread internationally amidst global deployment of precautionary measures to fight the illness. Some of the medications for COVID-19 are: Remdesivir (Veklury), Bebtelovimab, Molnupiravir (Lagevrio), Nirmatrelvir with ritonavir (Paxlovid) etc.